Ficonalkib is an investigational new drug that is being evaluated by Shouyao Holdings for the treatment of non-small cell lung cancer (NSCLC). It is an anaplastic lymphoma kinase (ALK) inhibitor.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.